Search Results
Urology and Preventive Medicine, and
Pathology, Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Search for other papers by J Kim in
Google Scholar
PubMed
Urology and Preventive Medicine, and
Pathology, Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Search for other papers by L Jia in
Google Scholar
PubMed
Urology and Preventive Medicine, and
Pathology, Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Search for other papers by M R Stallcup in
Google Scholar
PubMed
Urology and Preventive Medicine, and
Pathology, Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Search for other papers by G A Coetzee in
Google Scholar
PubMed
Introduction Untreated prostate cancer progresses from androgen-dependent tumors that respond favorably to clinical therapies to recurrent, metastatic, androgen-independent tumors that are invariably fatal. Even at the latter
Search for other papers by Anuradha Mishra in
Google Scholar
PubMed
National Institute of Animal Biotechnology (NIAB), Hyderabad, Telangana, India
Search for other papers by Nirmalya Ganguli in
Google Scholar
PubMed
National Institute of Animal Biotechnology (NIAB), Hyderabad, Telangana, India
Search for other papers by Subeer S Majumdar in
Google Scholar
PubMed
Search for other papers by Deepak Modi in
Google Scholar
PubMed
Introduction Endometrial cancer is the fourth most common malignancy in women. GLOBOCAN cancer statistics in 2020 estimated that 604,127 women globally, and 123,907 women in India alone had endometrial cancer ( Sung et al. 2021 ). Moreover
Search for other papers by Cinzia Puppin in
Google Scholar
PubMed
Search for other papers by Nadia Passon in
Google Scholar
PubMed
Search for other papers by Jerome M Hershman in
Google Scholar
PubMed
Search for other papers by Sebastiano Filetti in
Google Scholar
PubMed
Search for other papers by Stefania Bulotta in
Google Scholar
PubMed
Search for other papers by Marilena Celano in
Google Scholar
PubMed
Search for other papers by Diego Russo in
Google Scholar
PubMed
Dipartimento di Scienze Mediche e Biologiche, Department of Medicine, Dipartimento di Medicina Interna e Specialità Mediche, Dipartimento di Scienze Farmacobiologiche, Azienda Ospedaliero-Universitaria ‘S. Maria della Misericordia’, Università di Udine, Piazzale Kolbe 1, 33100 Udine, Italy
Search for other papers by Giuseppe Damante in
Google Scholar
PubMed
, Hingorani et al . 2010 ). In the majority of thyroid cancers, and particularly in metastatic lesions, reduction or abolition of NIS gene expression occurs very often ( Lazar et al . 1999 , Arturi et al . 2000 ). Loss of NIS gene expression is related
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
Search for other papers by Jack-Michel Renoir in
Google Scholar
PubMed
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
Search for other papers by Céline Bouclier in
Google Scholar
PubMed
Search for other papers by Amélie Seguin in
Google Scholar
PubMed
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
CNRS, Université Paris-Sud, IFR 141, Biologie moléculaire et cellulaire de la signalisation, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France
Search for other papers by Véronique Marsaud in
Google Scholar
PubMed
Search for other papers by Brigitte Sola in
Google Scholar
PubMed
breast cancer (BC) tumour behaviour and is much more strongly expressed in BC tumours than ERβ ( Dahlman-Wright et al . 2006 ). It is currently thought that ERβ represses growth by inhibiting ERα-mediated transcriptional activity ( Hall & McDonnell 1999
Cancer Biology Group, Dame Roma Mitchell Cancer Research Laboratories, Departments of Preventive Medicine and Urology, Level 1 Basil Hetzel Institute for Translational Health Research, Freemasons Foundation Centre for Men's Health, Queen Elizabeth Hospital, University of Adelaide, 28 Woodville Road, Woodville South, Adelaide, South Australia 5011, Australia
Search for other papers by Andrew P Trotta in
Google Scholar
PubMed
Search for other papers by Eleanor F Need in
Google Scholar
PubMed
Search for other papers by Lisa M Butler in
Google Scholar
PubMed
Search for other papers by Luke A Selth in
Google Scholar
PubMed
Search for other papers by Melissa A O'Loughlin in
Google Scholar
PubMed
Search for other papers by Gerhard A Coetzee in
Google Scholar
PubMed
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Search for other papers by Grant Buchanan in
Google Scholar
PubMed
be indicative of an altered status of receptor activation or response. This is most commonly observed in prostate cancer following the failure of androgen deprivation therapy, whereby the AR subcellular distribution shifts to become predominately
Search for other papers by Angela Nebbioso in
Google Scholar
PubMed
Dipartimento di Patologia Generale, Dipartimento di Patologia e Microbiologia Sperimentale, University of Southern Denmark, Dipartimento di Studi Farmaceutici, Department of Cancer Biology, Università degli Studi di Milano, CNR-IGB, Seconda Università di Napoli, 80138 Napoli, Italy
Search for other papers by Carmela Dell'Aversana in
Google Scholar
PubMed
Search for other papers by Anne Bugge in
Google Scholar
PubMed
Search for other papers by Roberta Sarno in
Google Scholar
PubMed
Search for other papers by Sergio Valente in
Google Scholar
PubMed
Search for other papers by Dante Rotili in
Google Scholar
PubMed
Dipartimento di Patologia Generale, Dipartimento di Patologia e Microbiologia Sperimentale, University of Southern Denmark, Dipartimento di Studi Farmaceutici, Department of Cancer Biology, Università degli Studi di Milano, CNR-IGB, Seconda Università di Napoli, 80138 Napoli, Italy
Search for other papers by Fabio Manzo in
Google Scholar
PubMed
Search for other papers by Diana Teti in
Google Scholar
PubMed
Search for other papers by Susanne Mandrup in
Google Scholar
PubMed
Search for other papers by Paolo Ciana in
Google Scholar
PubMed
Search for other papers by Adriana Maggi in
Google Scholar
PubMed
Search for other papers by Antonello Mai in
Google Scholar
PubMed
Search for other papers by Hinrich Gronemeyer in
Google Scholar
PubMed
Dipartimento di Patologia Generale, Dipartimento di Patologia e Microbiologia Sperimentale, University of Southern Denmark, Dipartimento di Studi Farmaceutici, Department of Cancer Biology, Università degli Studi di Milano, CNR-IGB, Seconda Università di Napoli, 80138 Napoli, Italy
Search for other papers by Lucia Altucci in
Google Scholar
PubMed
Introduction In the past years, epigenetic therapies have come of age. The finding that histone deacetylases (HDACs) often are more expressed in tumor cells gave credit to the application of HDAC inhibitors (HDACIs) to target cancer cells, without
Search for other papers by Jandee Lee in
Google Scholar
PubMed
Search for other papers by Mi-Youn Seol in
Google Scholar
PubMed
Search for other papers by Seonhyang Jeong in
Google Scholar
PubMed
Search for other papers by Hyeong Ju Kwon in
Google Scholar
PubMed
Search for other papers by Cho Rok Lee in
Google Scholar
PubMed
Search for other papers by Cheol Ryong Ku in
Google Scholar
PubMed
Search for other papers by Sang-Wook Kang in
Google Scholar
PubMed
Search for other papers by Jong Ju Jeong in
Google Scholar
PubMed
Search for other papers by Dong Yeob Shin in
Google Scholar
PubMed
Search for other papers by Kee-Hyun Nam in
Google Scholar
PubMed
Search for other papers by Eun Jig Lee in
Google Scholar
PubMed
Search for other papers by Woong Youn Chung in
Google Scholar
PubMed
Search for other papers by Young Suk Jo in
Google Scholar
PubMed
Introduction Papillary thyroid cancer (PTC) is the most common endocrine malignancy, and generally has favorable outcomes ( DeGroot et al . 1990 , Wada et al . 2003 , Pacini et al . 2006 , Kweon et al . 2013 ); however, a significant
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Search for other papers by Sandra E Ghayad in
Google Scholar
PubMed
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Search for other papers by Julie A Vendrell in
Google Scholar
PubMed
Search for other papers by Ivan Bieche in
Google Scholar
PubMed
Search for other papers by Frédérique Spyratos in
Google Scholar
PubMed
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Search for other papers by Charles Dumontet in
Google Scholar
PubMed
Search for other papers by Isabelle Treilleux in
Google Scholar
PubMed
Search for other papers by Rosette Lidereau in
Google Scholar
PubMed
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Université de Lyon, Université Lyon 1, INSERM, Centre Léon Bérard, Laboratoire d'Oncogénétique, Université Lyon 1, 69008 Lyon, France
Search for other papers by Pascale A Cohen in
Google Scholar
PubMed
Introduction Breast carcinoma, the most common female cancer, is currently undergoing an alarming increase. Breast cancer growth is regulated by estrogen, which acts by binding to the estrogen receptor α (ERα). ERα is routinely used as a prognostic
Search for other papers by Klaus W Frommer in
Google Scholar
PubMed
Search for other papers by Katharina Reichenmiller in
Google Scholar
PubMed
Search for other papers by Burkhardt S Schutt in
Google Scholar
PubMed
Search for other papers by Andreas Hoeflich in
Google Scholar
PubMed
Search for other papers by Michael B Ranke in
Google Scholar
PubMed
Search for other papers by Gabriele Dodt in
Google Scholar
PubMed
Search for other papers by Martin W Elmlinger in
Google Scholar
PubMed
in detail so far. One possible approach towards the identification of IGF-I-independent pathways of IGFBP-2 actions involves the human breast cancer cell line Hs578T, which possesses no functional IGF-I receptor, thereby excluding IGF
Department of Veterinary Physiology and Pharmacology, Institute of Biosciences and Technology, Veterinary Integrative Biosciences, Biochemistry and Biophysics, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, Texas 77843-4466, USA
Search for other papers by Kyounghyun Kim in
Google Scholar
PubMed
Search for other papers by Robert Burghardt in
Google Scholar
PubMed
Search for other papers by Rola Barhoumi in
Google Scholar
PubMed
Search for other papers by Syng-ook Lee in
Google Scholar
PubMed
Search for other papers by Xinyi Liu in
Google Scholar
PubMed
Department of Veterinary Physiology and Pharmacology, Institute of Biosciences and Technology, Veterinary Integrative Biosciences, Biochemistry and Biophysics, Texas A&M University, 4466 TAMU, Veterinary Research Building 410, College Station, Texas 77843-4466, USA
Search for other papers by Stephen Safe in
Google Scholar
PubMed
/tissue context-dependent manner ( Brooks & Gu 2006 ). Since MDM2 inhibits p53 function as a tumor suppressor gene, it is not surprising that expression of MDM2 plays a role in cancer and in cancer prognosis ( Levav-Cohen et al . 2005 ). Overexpression of MDM2 is